Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCSG 32: Neoadjuvant Trastuzumab, Docetaxel, Bevacizumab, and NPLD in HER2+ Breast Cancer
NCT01367028Phase 2Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Jun 2011
- Primary completion
- Apr 2014
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, non-pegylated liposomal doxorubicin in breast cancer, sponsored by Austrian Breast and Colorectal Cancer Study Group. Started Jun 2011; status: completed.
02
Drugs
bevacizumabnon-pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01367028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01367028.